Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment
Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now.
Arvinas Inc. (ARVN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,875,846 | $27,208,439 | +27% | 0.01% |
| 2. | Opaleye Management James A. Silverman | 1,975,000 | $13,864,500 | +22% | 3.09% |
| 3. | Alyeska Investment Group Anand Parekh | 1,800,000 | $12,636,000 | 0.05% | |
| 4. | Tang Capital Management Kevin C. Tang | 1,393,800 | $9,784,476 | 0.54% | |
| 5. | Millennium Management Israel Englander | 1,310,326 | $9,198,489 | +317% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.00 | 142,857 | $9,999,990.00 | 822,857 | 2020-12-18 | Filing | |
| $23.99 | 8,333 | $199,908.67 | 42,718 | 2020-11-09 | Filing | |
| $30.26 | 2,000 | $60,519.80 | 79,546 | 2020-06-17 | Filing | |
| $32.30 | 3,000 | $96,900.00 | 77,546 | 2020-06-02 | Filing | |
| $38.18 | 2,500 | $95,450.00 | 29,520 | 2020-03-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.61 | 5,700 | $43,377.00 | 164,401 | 2025-06-24 | Filing | |
| $7.49 | 2,583 | $19,346.67 | 154,248 | 2025-06-17 | Filing | |
| $8.59 | 8,658 | $74,372.22 | 110,023 | 2025-03-18 | Filing | |
| $16.75 | 1,214 | $20,334.50 | 18,863 | 2025-02-24 | Filing | |
| $16.55 | 1,146 | $18,966.30 | 97,231 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 66,858 | $492,075 | 0.15% | |
| 2. | 56,080 | $412,749 | 0.03% | |
| 3. | 50,366 | $370,694 | 0% | |
| 4. | 10,000 | $73,600 | 0% | |
| 5. | 872 | $6,418 | 0% |
News See All
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Arvinas, Inc. (NASDAQ:ARVN) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Gail and I will be the operator for today's call.
Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)
1 Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
10 Pump and Dump Stocks Favored by Hedge Funds
Pump and dump stocks are typically characterized by high 52-week volatility, often experiencing rapid price surges followed by sharp declines.
Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arvinas Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
10 Best Small-Cap Stocks Ready To Explode
On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief Investment Officer and Managing Director of Royce Investment, discussed the outperformance of small-cap stocks.
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I'd like to welcome everyone to Arvinas Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise.
Billionaire Hedge Funds
